>Marché des vaccins au Moyen-Orient et en Afrique, par composition (vaccins combinés, monovaccins), type (vaccins sous-unitaires, recombinants, polysaccharidiques et conjugués, vaccins vivants atténués, vaccins inactivés, vaccins toxoïdes, vaccins à ADN), type (vaccin de routine, vaccin recommandé, vaccin requis), âge d'administration (vaccin pédiatrique, vaccin adulte), maladies (maladie pneumococcique, rougeole, oreillons et varicelle, DTC, hépatite, grippe, typhoïde, méningocoque, rage, encéphalite japonaise, fièvre jaune, autres), voie d'administration (injectable, orale, nasale), utilisateur final (hôpitaux communautaires, hôpitaux, centres spécialisés, cliniques, autres), canal de distribution (pharmacie hospitalière, pharmacie de détail, pharmacie en ligne), pays (Arabie saoudite, Afrique du Sud, Émirats arabes unis, Israël, Koweït, Égypte, reste du Moyen-Orient et de l'Afrique) Tendances et prévisions de l'industrie 2028
Analyse et perspectives du marché : Marché des vaccins au Moyen-Orient et en Afrique
Le marché des vaccins devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 5,8 % au cours de la période de prévision de 2021 à 2028 et devrait atteindre 1 459,40 millions USD d'ici 2028. La forte prévalence de maladies chroniques telles que la grippe et les maladies infectieuses bactériennes et la présence de produits en cours de développement sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
Les vaccins sont des produits qui ont la capacité de réduire le risque de contracter une maladie en agissant sur le système immunitaire de l'organisme afin de renforcer la protection contre les agents pathogènes mortels. Différents types de vaccins ont été découverts contre des maladies potentiellement mortelles, ce qui permet d'éviter environ 2 à 3 millions de décès chaque année causés par des maladies telles que le tétanos, la diphtérie , la coqueluche, la rougeole et la grippe, entre autres.
Le lancement de nouveaux vaccins innovants renforce la confiance des patients et offre au marché un nouvel avenir qui peut avoir un effet positif sur la croissance du marché des vaccins. De plus, le lancement de nouveaux vaccins montre également que les acteurs du marché sont constamment engagés dans la croissance du marché des vaccins. Cela signifie donc que l'introduction de produits innovants agit comme un moteur de la croissance du marché des vaccins. Les processus de réglementation et la formation de documents des entreprises de fabrication dans différents pays peuvent entraver la croissance du marché des vaccins. Les acteurs du marché opérant sur le marché des vaccins adoptent plusieurs initiatives stratégiques qui devraient offrir des opportunités pour leurs activités dans diverses dimensions et mener la croissance du marché des vaccins. La peur des patients liée aux injections et aux piqûres d'aiguille constitue un défi pour la croissance du marché des vaccins.
Le rapport sur le marché des vaccins fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, les opportunités d'analyse en termes de poches de revenus émergentes, les changements dans la réglementation du marché, les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché des vaccins, contactez Data Bridge Market Research pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché des vaccins au Moyen-Orient et en Afrique
Le marché des vaccins est segmenté en fonction de la composition, du type, de la nature, de l'âge d'administration, des maladies, de la voie d'administration, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base de leur composition, le marché des vaccins est segmenté en vaccins combinés et monovaccins. En 2021, le segment des vaccins combinés domine le marché car les vaccins combinés sont efficaces contre plusieurs maladies par l'administration d'une seule injection.
- Sur la base du type, le marché des vaccins est segmenté en vaccins sous-unitaires, recombinants , polysaccharidiques et conjugués, vaccins vivants atténués, vaccins inactivés, vaccins toxoïdes et vaccins à ADN. En 2021, le segment des vaccins sous-unitaires, recombinants, polysaccharidiques et conjugués domine le marché car il a été signalé que ces vaccins induisent une forte réponse immunitaire chez presque toutes les personnes qui en ont besoin, y compris les personnes dont le système immunitaire est affaibli et qui ont des problèmes de santé à long terme.
- Sur la base du type de vaccin, le marché des vaccins est segmenté en vaccin de routine, vaccin recommandé et vaccin obligatoire. En 2021, le segment des vaccins de routine domine le marché car ils sont principalement utilisés pour la vaccination des enfants et les gouvernements accordent une importance majeure à la vaccination des enfants dans le monde entier.
- En fonction de l'âge d'administration, le marché des vaccins est segmenté en vaccins pédiatriques et vaccins pour adultes. En 2021, le segment des vaccins pédiatriques domine le marché car les enfants sont plus sujets aux maladies infectieuses, entre autres en raison du développement de leur système immunitaire, et ont donc besoin d'une vaccination appropriée.
- Sur la base des maladies, le marché des vaccins est segmenté en maladies pneumococciques, rougeole, oreillons et varicelle, DTC, hépatite , grippe, typhoïde, méningocoque, rage, encéphalite japonaise, fièvre jaune et autres. En 2021, le segment des maladies pneumococciques domine le marché en raison de la prévalence croissante de l'infection par la pneumonie et du lancement croissant de campagnes de vaccination pour le bien-être de la population.
- On the basis of route of administration, the vaccines market is segmented into injectable, oral and nasal. In 2021, injectable segment is dominating the market because most of the vaccines are administered via parenteral route and induces strong systemic response when injected via same route.
- On the basis of end user, the vaccines market is segmented into community hospitals, hospitals, specialty centres, clinics and others. In 2021, community hospitals segment is dominating the market because most of the vaccination and immunization is carried out by regulatory bodies and concerned authorities.
- On the basis of distribution channel, the vaccines market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. In 2021, hospital pharmacy segment is dominating the market because vaccines are directly procured from the company distributors.
Vaccines Market Country Level Analysis
The vaccines market is analyzed and market size information is provided on the basis of composition, type, kind, age of administration, diseases, route of administration, end user and distribution channel as referenced above.
The countries covered in the vaccines market report are the Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa.
Injectable segment in Middle East and Africa region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because injectable formulations give long lasting action in sustained release manner. Saudi Arabia is leading the growth of the Middle East and Africa market and injectable segment is dominating in this country due to rise in prevalence of flu related infection which related long time immunity.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Awareness for Vaccination and Launch of Newer Vaccines are Boosting the Market Growth of Vaccines
Vaccines market also provides you with detailed market analysis for every country growth in Vaccines industry with Vaccines drugs sales, impact of advancement in the Vaccines technology and changes in regulatory scenarios with their support for the Vaccines market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Vaccines Market Share Analysis
Le paysage concurrentiel du marché des vaccins fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise par rapport au marché des vaccins.
Les principales entreprises qui commercialisent ces vaccins sont Valneva SE, Takeda Pharmaceutical Company Limited, Abbott, AstraZeneca, Sanofi, Pfizer Inc., Janssen Global Services, LLC (une filiale de Johnson & Johnson Services, Inc.), F. Hoffmann-La Roche Ltd, Panacea Biotec Ltd, GlaxoSmithKline plc, entre autres acteurs mondiaux et nationaux. Les analystes de DBMR comprennent les atouts concurrentiels et fournissent une analyse concurrentielle pour chaque concurrent séparément.
De nombreux lancements de produits et accords sont également initiés par des entreprises du monde entier, ce qui accélère également le marché des vaccins.
Par exemple,
- En février 2020, Abbott a lancé un nouveau vaccin quadrivalent et sous-unitaire. Le vaccin lancé a la capacité de fournir une protection contre quatre souches virales de la grippe. Le produit lancé a renforcé le portefeuille de produits de l'entreprise et lui a permis de générer davantage de revenus.
- En juillet 2018, Sanofi a lancé en Inde le vaccin FluQuadri, qui offre une meilleure protection contre les quatre souches de vaccins antigrippaux. La plupart des vaccins disponibles contre la grippe étant de type trivalent, ce lancement de produit a permis à l'entreprise d'étendre sa présence sur le marché des vaccins et de connaître une croissance lucrative sur ce marché.
La collaboration, le lancement de produits, l'expansion commerciale, les récompenses et la reconnaissance, les coentreprises et d'autres stratégies des acteurs du marché améliorent le marché de l'entreprise sur le marché des vaccins, ce qui offre également l'avantage à l'organisation d'améliorer son offre de vaccins.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA VACCINES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 COMPOSITION LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 MIDDLE EAST & AFRICA VACCINES MARKET: LAWS AND REGULATIONS
8 MIDDLE EAST & AFRICA VACCINES MARKET: LOGISTICS OF VACCINES
8.1 COLD CHAIN STORAGE:
8.2 REGULATIONS ASSOCIATED WITH VACCINE SUPPLY
8.3 PROCESS OF LOGISTICS
8.4 CHALLENGES IN LOGISTICS
8.5 CHALLENGES FACED BY INDIA FOR UPCOMING COVID 19 VACCINE:
8.6 CHALLENGES FACED BY LATIN AMERICA FOR UPCOMING VACCINE:
8.7 CHALLENGES FACED BY NIGERIA FOR VACCINE LOGISTICS:
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS
9.1.2 HIGH PREVALENCE OF CHRONIC CONDITION SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES
9.1.3 IMPROVEMENT IN TREATMENT
9.1.4 LAUNCH OF NEWER VACCINES
9.1.5 INCREASING GOVERNMENT SUPPORT
9.2 RESTRAINTS
9.2.1 UNAVAILABILITY OF REGISTERED VACCINES
9.2.2 HIGH COST AND DIFFERENCES IN PRICING OF THE VACCINES
9.2.3 DIFFICULTIES ASSOCIATED WITH TRANSPORT AND PRODUCTION OF VACCINES
9.3 OPPORTUNITIES
9.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
9.3.2 PRESENCE OF PIPELINE PRODUCTS
9.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
9.3.4 INCREASING AWARENESS FOR VACCINATION
9.4 CHALLENGES
9.4.1 SIDE EFFECTS CAUSED BY VACCINES
9.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS
9.4.3 PRODUCT RECALL
10 IMPACT OF COVID-19 ON MIDDLE EAST & AFRICA VACCINES MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON SUPPLY CHAIN
10.3 IMPACT ON DEMAND
10.4 CONCLUSION
11 MIDDLE EAST & AFRICA VACCINES MARKET, BY COMPOSITION
11.1 OVERVIEW
11.2 COMBINATION VACCINES
11.3 MONO VACCINES
12 MIDDLE EAST & AFRICA VACCINES MARKET, BY TYPE
12.1 OVERVIEW
12.2 SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES
12.2.1 PNEUMOCOCCAL DISEASE
12.2.2 HIB (HAEMOPHILUS INFLUENZAE TYPE B) DISEASE
12.2.3 HPV (HUMAN PAPILLOMA VIRUS)
12.2.4 HEPATITIS B
12.2.5 MENINGOCOCCAL
12.2.6 SHINGLES
12.2.7 WHOOPING COUGH
12.2.8 OTHERS
12.3 LIVE-ATTENUTAED VACCINES
12.3.1 ROTAVIRUS
12.3.2 MEASLES
12.3.3 MUMPS
12.3.4 RUBELLA
12.3.5 SMALLPOX
12.3.6 YELLOW FEVER
12.3.7 OTHERS
12.4 INACTIVATED VACCINES
12.4.1 FLU (SHOT ONLY)
12.4.2 POLIO (SHOT ONLY)
12.4.3 HEPATITIS A
12.4.4 RABIES
12.4.5 OTHERS
12.5 TOXOID VACCINES
12.5.1 DIPHTHERIA, TETANUS & PERTUSSIS (DTP)
12.5.2 OTHERS
12.6 DNA VACCINES
13 MIDDLE EAST & AFRICA VACCINES MARKET, BY KIND
13.1 OVERVIEW
13.2 ROUTINE VACCINE
13.2.1 PNEUMOCOCCAL
13.2.2 DIPHTHERIA
13.2.3 HIB (HAEMOPHILUS INFLUENZAE TYPE B) DISEASE
13.2.4 MEASLES
13.2.5 MUMPS
13.2.6 HEPATITIS B
13.2.7 RUBELLA
13.2.8 POLIO
13.2.9 OTHERS
13.3 RECOMMENDED VACCINES
13.3.1 TYPHOID FEVER VACCINES
13.3.2 HEPATITIS A
13.3.3 RABIES
13.3.4 JAPANESE ENCEPHALITIS
13.3.5 TICK-BORNE ENCEPHALITIS
13.3.6 CHOLERA
13.3.7 OTHERS
13.4 REQUIRED VACCINES
13.4.1 MENINGOCOCCAL
13.4.2 YELLOW FEVER
13.4.3 OTHERS
14 MIDDLE EAST & AFRICA VACCINES MARKET, BY AGE OF ADMINISTRATION
14.1 OVERVIEW
14.2 PEDIATRIC VACCINES
14.2.1 PNEUMOCOCCAL
14.2.2 MEASLES, MUMPS, AND, RUBELLA
14.2.3 DIPHTHERIA, TETANUS & PERTUSIS (DPT)
14.2.4 ROTAVIRUS
14.2.5 MENINGOCOCCAL
14.2.6 VARICELLA
14.2.7 POLIO
14.2.8 TUBERCULOSIS
14.2.9 MALARIA
14.2.10 OTHERS
14.3 ADULT VACCINES
14.3.1 INLFUENZA
14.3.2 HPV (HUMAN PAPILLOMA VIRUS)
14.3.3 TYPHOID
14.3.4 HEPATITIS B
14.3.5 JAPANESE ENCEPHALITIS
14.3.6 YELLOW FEVER
14.3.7 HIV
14.3.8 CANCER
14.3.9 OTHERS
15 MIDDLE EAST & AFRICA VACCINES MARKET, BY DISEASES
15.1 OVERVIEW
15.2 PNEUMOCCOCAL DISEASE
15.3 MEASLES, MUMPS & RUBELLA
15.4 DPT
15.5 HEPATITIS
15.6 INFLUENZA
15.7 TYPHOID
15.8 MENINGOCOCCAL
15.9 VARICELLA
15.1 RABIES
15.11 JAPANESE ENCEPHALITIS
15.12 YELLOW FEVER
15.13 OTHERS
16 MIDDLE EAST & AFRICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION
16.1 OVERVIEW
16.2 INJECTABLE
16.2.1 INTRAMUSCULAR
16.2.2 SUBCUTANEOUS
16.2.3 INTRADERMAL
16.3 ORAL
16.4 NASAL
17 MIDDLE EAST & AFRICA VACCINES MARKET, BY END USER
17.1 OVERVIEW
17.2 COMMUNITY HOSPITALS
17.3 HOSPITALS
17.4 SPECIALTY CENTRES
17.5 CLINICS
17.6 OTHERS
18 MIDDLE EAST & AFRICA VACCINES MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.4 ONLINE PHARMACY
19 MIDDLE EAST & AFRICA VACCINES MARKET, BY GEOGRAPHY
19.1 MIDDLE EAST & AFRICA
19.1.1 SAUDI ARABIA
19.1.1.1 JORDAN
19.1.1.2 OMAN
19.1.1.3 QATAR
19.1.1.4 YEMEN
19.1.1.5 REST OF SAUDI ARABIA
19.1.2 SOUTH AFRICA
19.1.3 UAE
19.1.4 ISRAEL
19.1.5 KUWAIT
19.1.6 EGYPT
19.1.7 REST OF MIDDLE EAST & AFRICA
20 MIDDLE EAST & AFRICA VACCINES MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
21 COMPANY PROFILE
21.1 GLAXOSMITHKLINE PLC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.1.6 SWOT ANALYSIS
21.2 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.2.6 SWOT ANALYS
21.3 SANOFI
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.3.6 SWOT ANALYS
21.4 PFIZER INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.4.6 SWOT ANAL
21.5 ABBOTT
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 ALK
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENTS
21.7 ALTIMMUNE
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 ASTRAZENECA
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENTS
21.9 BAVARIAN NORDIC
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENTS
21.1 BAXTER VACCINES (A SUBSIDIARY OF BAXTER)
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 BHARAT BIOTECH
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENTS
21.12 BIO FARMA
21.12.1 COMPANY SNAPSHOT
21.12.2 PRODUCT PORTFOLIO
21.12.3 RECENT DEVELOPMENTS
21.13 BIOLOGICAL E LIMITED
21.13.1 COMPANY SNAPSHOT
21.13.2 PRODUCT PORTFOLIO
21.13.3 RECENT DEVELOPMENTS
21.14 DAIICHI SANKYO COMPANY, LIMITED
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 DYNAVAX TECHNOLOGIES
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 EMERGENT BIOSOLUTIONS INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 F. HOFFMANN-LA ROCHE LTD
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENT
21.18 JANSSEN MIDDLE EAST & AFRICA SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 LANZHOU BIOLOGICAL PRODUCTS RESEARCH INSTITUTE CO., LTD.,
21.19.1 COMPANY SNAPSHOT
21.19.2 PRODUCT PORTFOLIO
21.19.3 RECENT DEVELOPMENTS
21.2 PANACEA BIOTEC LTD
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 SEQIRUS (A SUBSIDIARY OF CSL LIMITED)
21.21.1 COMPANY SNAPSHOT
21.21.2 REVENUE ANALYSIS
21.21.3 PRODUCT PORTFOLIO
21.21.4 RECENT DEVELOPMENTS
21.21.5 SWOT ANALYSIS
21.22 SERUM INSTITUTE OF INDIA PVT. LTD.
21.22.1 COMPANY SNAPSHOT
21.22.2 PRODUCT PORTFOLIO
21.22.3 RECENT DEVELOPMENTS
21.23 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.23.1 COMPANY SNAPSHOT
21.23.2 REVENUE ANALYSIS
21.23.3 PRODUCT PORTFOLIO
21.23.4 RECENT DEVELOPMENTS
21.24 VALNEVA SE
21.24.1 COMPANY SNAPSHOT
21.24.2 REVENUE ANALYSIS
21.24.3 PRODUCT PORTFOLIO
21.24.4 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
Liste des tableaux
LIST OF TABLES
TABLE 1 MIDDLE EAST & AFRICA VACCINES MARKET, PIPELINE ANALYSIS
TABLE 2 REGULATIONS IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS
TABLE 3 RECOMMENDED TEMPERATURE AND STORAGE LENGTH AT VARIOUS LEVEL OF THE COLD CHAIN.
TABLE 4 PROCEDURES FOR REPORTING TO UNICEF VACCINE ARRIVALS.
TABLE 5 LOGISITCS PROCESS ACORSS DIFFERENT REGIONS.
TABLE 6 THE U.S. FUNDING FOR GAVI (2015-2019)
TABLE 7 PRICE OF THE VACCINES BETWEEN THE U.S. AND DEVELOPING COUNTRIES
TABLE 8 VACCINES UNDER CLINICAL TRIAL
TABLE 9 THE SIDE EFFECTS RELATED TO THE VACCINES
TABLE 10 INCREASE IN OPERATIONAL COST COMPONENTS DUE TO COVID-19
TABLE 11 TOTAL NUMBER OF CASES FOR MEASLES REPORTED BY THE TEN COUNTRIES
TABLE 12 MIDDLE EAST & AFRICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA COMBINATION VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA MONO VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA INACTIVATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA TOXOID VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA ROUTINE VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA RECOMMENDED VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA REQUIRED VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA PEDIATRIC VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA ADULT VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA PNEUMOCOCCAL DISEASE IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA MEASLES, MUMPS & RUBELLA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA DPT IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA HEPATITIS IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA INFLUENZA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA TYPHOID IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA MENINGOCOCCAL IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA VARICELLA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA RABIES IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA JAPANESE ENCEPHALITIS IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA YELLOW FEVER IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA OTHER IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA INJECTABLE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA ORAL IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA NASAL IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA COMMUNITY HOSPITALS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA HOSPITALS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA SPECIALTY CENTRES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA CLINICS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA OTHERS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA RETAIL PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA ONLINE PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA VACCINES MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 MIDDLE EAST & AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 MIDDLE EAST & AFRICA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 MIDDLE EAST & AFRICA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 MIDDLE EAST & AFRICA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 70 MIDDLE EAST & AFRICA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 71 MIDDLE EAST & AFRICA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 72 MIDDLE EAST & AFRICA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 73 MIDDLE EAST & AFRICA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 74 MIDDLE EAST & AFRICA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 75 MIDDLE EAST & AFRICA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 76 MIDDLE EAST & AFRICA VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 77 MIDDLE EAST & AFRICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 MIDDLE EAST & AFRICA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 79 MIDDLE EAST & AFRICA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 80 MIDDLE EAST & AFRICA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 92 SAUDI ARABIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 94 SAUDI ARABIA VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 95 SAUDI ARABIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 SAUDI ARABIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 SAUDI ARABIA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 98 SAUDI ARABIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 99 JORDAN VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 100 JORDAN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 101 JORDAN SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 JORDAN LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 JORDAN INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 JORDAN TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 JORDAN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 106 JORDAN ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 107 JORDAN RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 108 JORDAN REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 109 JORDAN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 JORDAN PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 111 JORDAN ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 112 JORDAN VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 113 JORDAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 114 JORDAN INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 115 JORDAN VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 116 JORDAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 117 OMAN VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 118 OMAN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 119 OMAN SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 120 OMAN LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 OMAN INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 OMAN TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 OMAN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 124 OMAN ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 125 OMAN RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 126 OMAN REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 127 OMAN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 128 OMAN PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 129 OMAN ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 130 OMAN VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 131 OMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 132 OMAN INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 133 OMAN VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 134 OMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 135 QATAR VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 136 QATAR VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 QATAR SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 QATAR LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 139 QATAR INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 140 QATAR TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 141 QATAR VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 142 QATAR ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 143 QATAR RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 144 QATAR REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 145 QATAR VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 146 QATAR PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 147 QATAR ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 148 QATAR VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 149 QATAR VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 150 QATAR INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 151 QATAR VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 152 QATAR VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 153 YEMEN VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 154 YEMEN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 YEMEN SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 YEMEN LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 YEMEN INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 YEMEN TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 YEMEN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 160 YEMEN ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 161 YEMEN RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 162 YEMEN REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 163 YEMEN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 164 YEMEN PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 165 YEMEN ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 YEMEN VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 167 YEMEN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 168 YEMEN INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 169 YEMEN VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 170 YEMEN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 171 REST OF SAUDI ARABIA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 172 REST OF SAUDI ARABIA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 REST OF SAUDI ARABIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 REST OF SAUDI ARABIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 REST OF SAUDI ARABIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 REST OF SAUDI ARABIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 REST OF SAUDI ARABIA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 178 REST OF SAUDI ARABIA ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 179 REST OF SAUDI ARABIA RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 180 REST OF SAUDI ARABIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 181 REST OF SAUDI ARABIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 182 REST OF SAUDI ARABIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 183 REST OF SAUDI ARABIA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 REST OF SAUDI ARABIA VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 185 REST OF SAUDI ARABIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 186 REST OF SAUDI ARABIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 187 REST OF SAUDI ARABIA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 188 REST OF SAUDI ARABIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 189 SOUTH AFRICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 190 SOUTH AFRICA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 SOUTH AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 SOUTH AFRICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 SOUTH AFRICA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 SOUTH AFRICA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 SOUTH AFRICA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 196 SOUTH AFRICA ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 197 SOUTH AFRICA RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 198 SOUTH AFRICA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 199 SOUTH AFRICA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 200 SOUTH AFRICA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 201 SOUTH AFRICA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 202 SOUTH AFRICA VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 203 SOUTH AFRICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 204 SOUTH AFRICA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 205 SOUTH AFRICA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 206 SOUTH AFRICA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 207 UAE VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 208 UAE VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 209 UAE SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 210 UAE LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 211 UAE INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 212 UAE TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 213 UAE VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 214 UAE ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 215 UAE RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 216 UAE REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 217 UAE VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 218 UAE PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 219 UAE ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 220 UAE VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 221 UAE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 222 UAE INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 223 UAE VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 224 UAE VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 225 ISRAEL VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 226 ISRAEL VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 ISRAEL SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 228 ISRAEL LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 229 ISRAEL INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 230 ISRAEL TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 231 ISRAEL VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 232 ISRAEL ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 233 ISRAEL RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 234 ISRAEL REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 235 ISRAEL VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 236 ISRAEL PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 237 ISRAEL ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 238 ISRAEL VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 239 ISRAEL VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 240 ISRAEL INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 241 ISRAEL VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 242 ISRAEL VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 243 KUWAIT VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 244 KUWAIT VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 245 KUWAIT SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 246 KUWAIT LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 247 KUWAIT INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 248 KUWAIT TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 249 KUWAIT VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 250 KUWAIT ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 251 KUWAIT RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 252 KUWAIT REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 253 KUWAIT VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 254 KUWAIT PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 255 KUWAIT ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 256 KUWAIT VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 257 KUWAIT VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 258 KUWAIT INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 259 KUWAIT VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 260 KUWAIT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 261 EGYPT VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 262 EGYPT VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 263 EGYPT SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 264 EGYPT LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 265 EGYPT INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 266 EGYPT TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 267 EGYPT VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 268 EGYPT ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 269 EGYPT RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 270 EGYPT REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 271 EGYPT VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 272 EGYPT PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 273 EGYPT ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 274 EGYPT VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 275 EGYPT VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 276 EGYPT INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 277 EGYPT VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 278 EGYPT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 279 REST OF MIDDLE EAST & AFRICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
Liste des figures
LIST OF FIGURES
FIGURE 1 MIDDLE EAST & AFRICA VACCINES MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA VACCINES MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA VACCINES MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA VACCINES MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA VACCINES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA VACCINES MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST & AFRICA VACCINES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST & AFRICA VACCINES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA VACCINES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA VACCINES MARKET: SEGMENTATION
FIGURE 11 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS AND HIGH PREVALENCE OF CHRONIC CONDITION SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES ARE DRIVING THE MIDDLE EAST & AFRICA VACCINES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA VACCINES MARKET IN 2021 & 2028
FIGURE 13 FDA REGULATORY REVIEW PROCESS OF VACCINES
FIGURE 14 AEFI ORGANIZATIONAL STRUCTURES
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA VACCINES MARKET
FIGURE 16 MIDDLE EAST & AFRICA VACCINATION COVERAGE IN THE WORLD (2019)
FIGURE 17 PEDIATRIC DEATHS CAUSED BY INFLUENZA IN THE U.S. (2017 – 2020)
FIGURE 18 MIDDLE EAST & AFRICA PREVALENCE OF HBV INFECTION WORLDWIDE IN 2018
FIGURE 19 HEALTHCARE EXPENDITURE PER CAPITA, 2018
FIGURE 20 TOTAL NUMBER OF CASES FOR MEASLES REPORTED BY THE TEN COUNTRIES
FIGURE 21 MIDDLE EAST & AFRICA VACCINES MARKET: BY COMPOSITION, 2021
FIGURE 22 MIDDLE EAST & AFRICA VACCINES MARKET: BY COMPOSITION, 2019-2028 (USD MILLION)
FIGURE 23 MIDDLE EAST & AFRICA VACCINES MARKET: BY COMPOSITION, CAGR (2021-2028)
FIGURE 24 MIDDLE EAST & AFRICA VACCINES MARKET: BY COMPOSITION, LIFELINE CURVE
FIGURE 25 MIDDLE EAST & AFRICA VACCINES MARKET: BY TYPE, 2021
FIGURE 26 MIDDLE EAST & AFRICA VACCINES MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 27 MIDDLE EAST & AFRICA VACCINES MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 28 MIDDLE EAST & AFRICA VACCINES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 29 MIDDLE EAST & AFRICA VACCINES MARKET: BY KIND, 2019
FIGURE 30 MIDDLE EAST & AFRICA VACCINES MARKET: BY KIND, 2019-2028 (USD MILLION)
FIGURE 31 MIDDLE EAST & AFRICA VACCINES MARKET: BY KIND, CAGR (2021-2028)
FIGURE 32 MIDDLE EAST & AFRICA VACCINES MARKET: BY KIND, LIFELINE CURVE
FIGURE 33 MIDDLE EAST & AFRICA VACCINES MARKET: BY AGE OF ADMINISTRATION, 2019
FIGURE 34 MIDDLE EAST & AFRICA VACCINES MARKET: BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 35 MIDDLE EAST & AFRICA VACCINES MARKET: BY AGE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 36 MIDDLE EAST & AFRICA VACCINES MARKET: BY AGE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 37 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISEASES, 2020
FIGURE 38 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISEASES, 2019-2028 (USD MILLION)
FIGURE 39 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISEASES, CAGR (2021-2028)
FIGURE 40 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 41 MIDDLE EAST & AFRICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 42 MIDDLE EAST & AFRICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 43 MIDDLE EAST & AFRICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 44 MIDDLE EAST & AFRICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 45 MIDDLE EAST & AFRICA VACCINES MARKET: BY END USER, 2019
FIGURE 46 MIDDLE EAST & AFRICA VACCINES MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 47 MIDDLE EAST & AFRICA VACCINES MARKET: BY END USER, CAGR (2021-2028)
FIGURE 48 MIDDLE EAST & AFRICA VACCINES MARKET: BY END USER, LIFELINE CURVE
FIGURE 49 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 50 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 51 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 52 MIDDLE EAST & AFRICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 53 MIDDLE EAST & AFRICA VACCINES MARKET: SNAPSHOT (2020)
FIGURE 54 MIDDLE EAST & AFRICA VACCINES MARKET: BY COUNTRY (2020)
FIGURE 55 MIDDLE EAST & AFRICA VACCINES MARKET: BY COUNTRY (2021 & 2028)
FIGURE 56 MIDDLE EAST & AFRICA VACCINES MARKET: BY COUNTRY (2020 & 2028)
FIGURE 57 MIDDLE EAST & AFRICA VACCINES MARKET: BY TYPE (2021-2028)
FIGURE 58 MIDDLE EAST & AFRICA VACCINES MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
